Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Hormone therapy stories

Oct 30, 2026

FDA removes black box warning from three estradiol transdermal patches for menopause

The U.S. Food and Drug Administration approved the removal of black box warnings from three estradiol transdermal patches used to treat menopause symptoms. The strictest FDA warnings had previously cautioned about risks of cardiovascular disease, breast cancer, and dementia.

Oct 30, 2026·3 sources
00
Oct 23, 2026

US estrogen shortage expands beyond patches to injectable and vaginal products

Women in the US seeking hormone replacement therapy for menopause symptoms are facing widening shortages that now extend beyond estrogen patches to include injectable and vaginal estrogen products, driven by surging demand.

Oct 23, 2026·3 sources
00
Aug 14, 2026

Women taking estrogen-only hormone therapy showed fewer Alzheimer's signs in brain tissue

A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.

Aug 14, 2026·3 sources
00
Aug 7, 2026

Breast tumor microenvironment cells may predict tamoxifen treatment effectiveness, study finds

Research from Karolinska Institutet published in BMC Medicine reveals that the types of cells surrounding a breast tumor may influence the long-term effectiveness of tamoxifen hormone therapy, potentially helping identify which patients benefit most from the treatment.

Aug 7, 2026·1 source
00
Jul 29, 2026

FDA Approves Gwyn Lo, First Once-Weekly Low-Dose Estrogen Birth Control Patch

The FDA has approved Gwyn Lo (Viatris), a new contraceptive patch that delivers norelgestromin and low-dose estrogen hormones through once-weekly administration for pregnancy prevention.

Jul 29, 2026·1 source
00

Top claims

  • ▪In July 2025, the U.S. Food and Drug Administration convened an expert panel on menopausal hormone therapy featuring vocal proponents of hormone replacement therapy while denying public testimony from audience members.
  • ▪A U.S. Food and Drug Administration spokesperson previously stated last November that the agency bypassed advisory committees because they are bureaucratic, costly, and often conflicted.
  • ▪National Institute of Child Health and Human Development deputy director Dorothy Fink stated that U.S. market output for estrogen patches has doubled over the past year.

People involved

Robert F. Kennedy Jr.Donald Trump

Subtopics

Drug Policy, Pricing & Approval4Women's health3Drug Approval and Clinical Trials2Drug shortages2Menopause2Menopause hormone therapy and symptom management2Reproductive Health2Reproductive hormones2Women's reproductive health & fertility2Age related cognitive decline1Aging (Biology)1Alzheimer’s & dementia1Alzheimer's disease1Brain longevity1Cognitive decline1Contraception & birth control access1Drug labeling & regulation1FDA regulation1Government and Regulatory Policy1Healthcare access1Mental Health & Wellbeing1Neurodiversity & Cognitive Function1Personalized medicine1Pharmaceutical supply chain1

Related timelines

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories